Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

On the staircase to FY26, with a FY25 skew to 2H25

Cleanaway Waste Management
3:27pm
February 19, 2025
1H25 earnings/cashflow was short of expectations, but CWY continues to paint a positive picture of the momentum for delivery of its FY26 targets (and beyond). Forecast changes are minimal. 12 month target price set at $2.85 based on DCF. HOLD retained, given c.8% TSR at current prices (including c.2% cash yield).

Uncertainty lingers

Ventia Services Group
3:27pm
February 19, 2025
VNT reported a strong FY24 result with EBITDA +7% YoY and NPATA +13%. FY25 guidance is for +7-10% NPATA growth, which takes into account all “risks and opportunities” in the year ahead, notwithstanding the ACCC uncertainty and a large amount of defence contracts coming up for renewal in June. We had previously assumed all the ~$500m of defence EMOS revenues due for expiry in June would be lost, however, we now assume ~$250m. This sees our FY25 NPATA forecast increase by +18%. We are now forecasting NPATA growth of +9% in FY25, though this falls to just +1% in FY26 with the full-year effect of lost defence revenue. Given the earnings and perception uncertainty surrounding the ACCC proceedings, we maintain the Hold rating and still ascribe a discount (~15%) to our valuation. PT moves to $4.05. With this report, we transfer coverage to Nicholas Rawlinson.

1H25 Result: Shape shifting

Step One Clothing
3:27pm
February 19, 2025
Step One (ASX: STP) delivered EBITDA broadly in line with expectations, but the way it got there was quite different. A strategic pivot towards the minimisation of brand marketing in the US, STP’s smallest market, meant sales there were much lower than expected. The gross margin was also lower than anticipated as the discounts offered during sales events had a bigger effect than we had thought. The efficiency of marketing expenditure was much better, though, more than offsetting lower sales and gross margins. The shape of the P&L in 1H25 looks to us like the best guide to the future. We have updated our model accordingly, with the result that forecast sales and gross profit fall, but EBITDA increases by 1% in FY25 and FY26. At a FY26F P/E of 12x, it is our opinion that STP is too cheap for a business capable of delivering c.10% growth in EBITDA each year over the next few years. We retain our ADD recommendation. Lead coverage of Step One passes to Emily Porter with this note.

The going gets tougher

Mineral Resources
3:27pm
February 19, 2025
We saw the overall result and subsequent 2H’FY25 outlook provided by MIN as negative. Group underlying EBITDA of $302m (vs Visible Alpha consensus/MorgansF $205m/$252m) beat expectations on Mining Services EBITDA but downgrades to FY25 Onslow and mining services guidance increases to FY25 capital expenditure guidance and continued issues on MIN’s Onslow Haul Road disappointed the market. Net debt now sits at ~$5.1bn and despite MIN expecting peak net debt this 1H25, we don’t expect a material step down in net debt until the end of the decade. Our target price has reduced by -26% to A$26ps (previously A$35ps) and we maintain our Hold rating following a subsequent -20% in share price post the result release.

Set to benefit from improved home affordability

James Hardie Industries
3:27pm
February 19, 2025
The HY25 result was largely in line with consensus expectations (and a slight beat vs our forecasts), with the company’s cost discipline offsetting what remain challenging end markets and raw material cost headwinds. Despite these challenges, the company is confident in its FY25 earnings guidance, along with the capacity to accelerate its outperformance should markets recover on the back of improved housing affordability – demonstrated by management’s commitment to margin expansion in FY26, despite forecasting high single-digit raw material cost inflation. We reiterate our Add rating at a A$60.00/sh price target.

Solid 1H performance - new CEO to step in

Ebos Group
3:27pm
February 19, 2025
EBO posted a solid 1H25 result with underlying EBITDA of A$291.0m (MorgansF A$283.6m) and in line with consensus. Importantly, FY25 guidance of underlying EBITDA between A$575m to A$600m was reconfirmed. The share price has been strong (up 13.8%) over last month and some profit taking has come into the price post the release of the result. Long term CEO will retire at 30 June being replaced by an ex-Orica executive. We have made changes to our amortisation, interest and one-off costs forecasts which results in a ~6.1% downgrade and sees our TP reduce to A$38.56 (was A$39.04). Add maintained.

Coming in with confidence in growth

Data#3
3:27pm
February 19, 2025
DTL’s 1H25 came in towards the upper end of expectations and guidance (excluding one-off restructuring charges). The key focus for most investors, ourselves included was in understanding the broader implications of Microsoft rebate changes, which were announced last year. DTL management sounded confident in their capacity to offset these headwinds despite changes being larger and faster than normal. Rebate changes are BAU for DTL, albeit not typically as large or implemented as quickly, as recently. Overall, we upgrade our EPS forecasts by 3-6% and our Target Price increases to $7.50 per share. Hold recommendation retained.

Another contract win

Findi
3:27pm
February 19, 2025
FND has announced it has secured an additional 2,293 ATMs from the State Bank of India (SBI). This follows on quickly from another recent Brown Label ATM (BLA) contract FND signed with the Union Bank of India. Meanwhile, FY25 revenue and EBITDA guidance has been lowered on a delay to the start of FND’s White Label ATM strategy. We reduce our FND FY25F/FY26F EPS by >10% (off low bases) reflecting lowered FY25 guidance expectations. However our price target rises to A$7.95 (previously A$7.68) on the long-term financial benefits stemming from the new SBI deal. FND’s management appear to be executing well on the company’s overall build out and with +35% upside to our blended valuation (A$7.95), we maintain our ADD call. We reduce our FND FY25F/FY26F EPS by >10% (off low bases) reflecting lowered FY25 guidance expectations. However, our price target rises to A$7.95 (previously A$7.68) on the long-term financial benefits stemming from the new SBI deal.

Approaching major Ph3 readout in 2025

Dimerix
3:27pm
February 19, 2025
Dimerix (DXB) is a clinical-stage biopharmaceutical company focused on developing treatments for kidney and respiratory diseases through its product pipeline. Positive results from the second interim analysis of 144 patients expected in August 2025 is a major catalyst. DXB notes the potential to receive accelerated marketing approval if results are positive, significantly advancing its availability as a treatment for FSGS. DXB remains positive about its long-term prospects as it continues to advance its ACTION3 program to treat FSGS, alongside other commercially promising developments in its pipeline, such as the DMX-700 treatment for COPD.

Investment revs up

ARB Corporation
3:27pm
February 18, 2025
ARB reported a softer 1H25 result, delivering sales +5.9%; costs +9.1%; and underlying NPAT down -4.6% (NPAT -5% below VA consensus). We continue to rate ARB as a high-quality business with an exciting offshore expansion opportunity in the US ahead. Understandably, the group is working through a period of increased investment to realise value on this undertaking. While we are supportive of this, we are wary of coinciding slowing domestic aftermarket sales detracting from the near-term growth outlook. Hold maintained.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more